CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Program Title

Update on the Management of Chronic Constipation in Long-Term Care
Release Date: January-15-07
Credit Expiration Date: March-31-08


James C. Eoff III, PharmD
Executive Associate Dean
University of Tennessee College of Pharmacy
Memphis, Tennessee

Lucinda A. Harris, MS, MD
Senior Associate Consultant
Mayo Clinic Division of Gastroenterology & Hepatology
Scottsdale, Arizona

Credit Hours



Online Presentation

Program Description

Constipation is a common condition in individuals 65 years and older and affects approximately 26% of elderly men and 34% of elderly women. The disorder is attributed to 2.5 million physician office visits in the US per year and is a major contributor to diminished quality of life.

Special attention must be paid to elderly constipation patients especially if they reside in a long-term care facility. The etiology of chronic constipation in this population is multi-faceted and includes reduced physical exercise, issues with eating habits, functional limitations from prior strokes, depression and psychological distress, structural abnormalities, metabolic and neurologic comorbidities, and medication use.

Traditional laxatives and fiber supplements often do not provide adequate relief of symptoms and may lead to further impairment of quality of life, higher health care utilization, and polypharmacy. However, recent advances in drug development have led to some promising agents that effectively treat chronic idiopathic constipation. Because of the overwhelming prevalence of constipation in the elderly, health care professionals working in long-term care settings need to be informed and educated about the causes and complications of constipation and available treatment strategies that effectively manage the condition.

Update on the Management of Chronic Constipation in Long-Term Care will identify primary and secondary constipation causes, and discuss disease burden and quality of life issues associated with constipation in long-term care residents. In addition, this educational activity will evaluate traditional and newer treatment options for elderly chronic constipation patients based on specific criteria of drug interactions, patient age, health, and other factors.

Program Developer/Facilitator


Target Audience

This program has been developed specifically for consultant pharmacists, long-term care medical directors, VA pharmacists, nurse practitioners, and nurses involved in long-term care.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Differentiate primary and secondary constipation causes in long-term care elderly patients, including transit time, dyssynergia, comorbidities, diet, and medication use
  2. Review diagnostic evidence to differentiate chronic constipation (CC) from constipation predominant IBS
  3. Discuss disease burden, related complications, and quality of life issues associated with constipation in long-term care residents
  4. Evaluate traditional and newer treatment options for elderly constipation patients based on specific criteria of drug interactions, patient age, health, and other factors


It is the policy of ASCP, in accordance with the guidelines set forth by the Accreditation Council for Pharmacy Education, and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by ASCP and AKH prior to accreditation of the activity.

The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speakers’ interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.

James C. Eoff III, PharmD has no commercial interests to disclose.

Lucinda A. Harris, MS, MD has received compensation as a member of speakers' bureaus for Sucampo Pharmaceuticals, Inc. & Takeda Pharmaceuticals North America, Inc. and Novartis Pharmaceuticals Corporation.

Credit Statements

ASCP is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is accredited for 1.0 contact hour (0.1 CEUs) of continuing education credit. Universal Program Number 203-999-07-001-H01.

NADONA/LTC is an approved provider of continuing nursing education by Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation #1087. This program has been approved for 1 contact hour by NADONA/LTC.

AKH Inc. is accredited by the American Academy of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. AKH Inc. designates this educational activity for 1.0 contact hour which includes 0.3 pharmacology hours.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The release date of this activity is: January 15, 2007.

Participants must successfully complete the posttest (70% or higher) and submit an evaluation to receive credit.

Commercial Support Statements

Supported by an educational grant from Sucampo Pharmaceuticals, Inc. & Takeda Pharmaceuticals North America, Inc.


Please turn off all pop-up blockers to assure access to the educational activity.

  1. Click on the "Start program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
  2. The next main menu screen will permit you to check for or download the Flash player required to run this program. Clicking on "slides" on this screen will begin the program presentation. You may return to this main menu to view the question and answer segment, the reference list, and the CME/CE post-test and evaluation. The program will take approximately 60 minutes to complete.
  3. Upon completion of the program, click on the post-test button to register and/or access the post-test and program evaluation. Please note that a link to the ASCP website is provided for all pharmacists requesting CPE credit.
  4. Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CPE/CE certificate/statement.

Certificate Fee



None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication and audioconference are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., the American Society of Consultant Pharmacists, the National Association of Directors of Nursing Administration in Long-Term Care, Sucampo Pharmaceuticals, Inc or Takeda Pharmaceuticals North America, Inc. Any medications or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu